A scientific advisory board (SAB) is a group of outside experts who provide non-binding guidance to an organization on scientific, technical, or research-related decisions. Unlike a board of directors, an SAB has no legal authority over the organization. Its role is purely consultative: members offer specialized knowledge that the organization’s internal team doesn’t have, helping leadership make better-informed decisions without actually making those decisions themselves.
SABs are common in biotech and pharmaceutical companies, government agencies, nonprofits, and academic research projects. Their influence can be significant even without formal power, shaping everything from which drug candidates move forward in a pipeline to how a government agency responds to a public health crisis.
How an SAB Differs From a Board of Directors
The distinction matters because the two boards operate under completely different rules. A board of directors is legally responsible for an organization. Its members have fiduciary duties, meaning they are legally obligated to act in the organization’s best interest. They make binding decisions: approving budgets, hiring executives, setting strategic goals. Their authority is defined in organizational bylaws and regulated by law.
An SAB carries none of that legal weight. Members have no fiduciary responsibilities and no liability for the organization’s outcomes. They offer recommendations and insights, but the organization is free to ignore them entirely. This lighter structure is actually part of the appeal. It lets organizations tap into high-level expertise without the governance complexity and legal obligations that come with adding someone to a fiduciary board.
Compensation reflects this difference. Advisory board members at private companies typically earn 65% to 75% of what fiduciary board members receive. For context, the median annual retainer for a private company fiduciary board member in 2025 is around $38,800, with per-meeting fees near $2,500 and long-term incentive grants around $50,000. SAB members in biotech startups are often compensated partly in equity, giving them a financial stake in the company’s success while keeping cash costs low.
What SAB Members Actually Do
The core function is filling knowledge gaps. Organizations convene SABs to access expertise they don’t have in-house and to get an independent perspective on their work. In practice, this plays out in several ways depending on the sector.
At biotech and pharmaceutical companies, SAB members review research and development activities and help management make scientific judgments about their product pipeline. Amgen, for example, uses its SABs specifically for external scientific review of R&D and to assist with portfolio decisions. This might mean evaluating whether a drug candidate’s early data justifies moving into expensive clinical trials, identifying flaws in a study design before it launches, or assessing how a regulatory agency is likely to view a particular set of results.
In government and international organizations, scientific advisory committees serve a broader role. At the World Health Organization, these committees help build consensus on politically sensitive scientific issues, provide evidence-based cover for controversial recommendations, and serve as “testing grounds” for ideas the agency isn’t yet ready to promote on its own. Government SABs often function as a bridge between raw scientific evidence and policy decisions, translating complex data into actionable guidance for officials who aren’t scientists.
For research projects and nonprofits, SABs tend to be more hands-on. Members might review a project’s main deliverable, work through design challenges the team is struggling with, or identify weaknesses in a research proposal. The advisory role here is less about high-level strategy and more about improving the quality of the work itself.
Who Serves on an SAB
The baseline requirement is deep expertise in the relevant field. At the NIH, the principal requirement for scientific review committees is competence as an independent investigator, assessed through research accomplishments, publications, and other scientific achievements. A doctoral degree or equivalent is usually expected.
But many SABs extend beyond pure scientists. NIH advisory councils, for instance, are required by law to be composed of two-thirds scientific members and one-third public representatives. Those public members might include leaders in law, economics, health policy, management, or public policy. The goal is to balance technical depth with a broader perspective on how scientific work connects to real-world needs.
For a biotech startup, an SAB might include academic researchers whose work is directly relevant to the company’s technology, clinicians who treat the disease the company is targeting, former regulatory officials who understand what agencies look for in approval applications, and occasionally a well-known name whose reputation lends credibility with investors. The composition is always tailored to whatever gaps the organization most needs to fill.
Managing Conflicts of Interest
Because SAB members are outside experts, they often have financial ties or professional relationships that could bias their advice. Conflict of interest management is a central concern in any well-run advisory board.
The CDC’s approach to its vaccine advisory committees illustrates standard practice. Members are screened for potential conflicts when they join, and those screenings are updated annually. A conflict exists whenever a member has a financial interest in a product, a competing product, or a manufacturer that could bias their recommendations. Members are personally responsible for flagging any conflicts that arise, and if they feel unable to provide objective advice on a particular topic, they must step back from that portion of the committee’s work.
Independence is a three-dimensional problem. For an SAB to function properly, members need autonomy from the organization that convened them (so they aren’t just telling leadership what it wants to hear), from the institutions where they work (so their employer’s interests don’t color their advice), and from whatever entities will act on the recommendations. Achieving all three simultaneously is difficult, and the staff supporting an SAB often have to balance protecting the board’s independence against staying connected enough to the political or business environment that the advice remains relevant and actionable.
How Meetings Typically Work
Most SABs meet a few times per year. A common structure is one in-person meeting annually, supplemented by virtual meetings roughly three times a year, each lasting about 90 minutes. In-person meetings tend to be more intensive, sometimes spanning two full days, with structured agendas designed to keep experts actively engaged rather than passively listening to presentations.
Effective SAB meetings avoid the trap of long, one-directional presentations. Instead, they mix formats: small-group discussions, paired conversations, design tasks where advisors work through real problems the organization faces, short individual presentations from each member highlighting relevant aspects of their own work, and panel discussions organized by expertise area. The goal is to extract as much useful thinking from a room full of busy experts as possible in a limited window.
Between meetings, SAB members may review documents, respond to specific questions from the organization, or make introductions within their professional networks. The level of between-meeting engagement varies widely. Some SABs are essentially meeting-only arrangements, while others involve ongoing informal consultation.
Why Organizations Invest in SABs
The practical value comes down to better decisions and external credibility. Internally, an SAB gives leadership access to perspectives they wouldn’t otherwise have, catches blind spots in technical strategy, and provides a reality check from people who don’t have the same organizational biases as employees. Externally, a strong SAB signals to investors, regulators, and partners that the organization’s scientific direction has been vetted by respected independent experts.
For early-stage biotech companies, an impressive SAB can be the difference between securing funding and being passed over. Investors often look at who is advising a company as a proxy for the quality of its science. For government agencies, advisory committees provide the evidence-based legitimacy needed to justify policy decisions that might otherwise face political pushback. The committee becomes a credible, independent voice that policymakers can point to when defending a controversial recommendation.